Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2005 7
2006 4
2007 4
2008 7
2009 8
2010 18
2011 17
2012 32
2013 36
2014 49
2015 54
2016 54
2017 55
2018 59
2019 84
2020 103
2021 124
2022 161
2023 176
2024 63

Text availability

Article attribute

Article type

Publication date

Search Results

1,015 results

Results by year

Filters applied: . Clear all
Page 1
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Liu Y, Zhu XZ, Xiao Y, Wu SY, Zuo WJ, Yu Q, Cao AY, Li JJ, Yu KD, Liu GY, Wu J, Sun T, Cui JW, Lv Z, Li HP, Zhu XY, Jiang YZ, Wang ZH, Shao ZM. Liu Y, et al. Cell Res. 2023 May;33(5):389-402. doi: 10.1038/s41422-023-00795-2. Epub 2023 Mar 27. Cell Res. 2023. PMID: 36973538 Free PMC article. Clinical Trial.
Red Blood Cell and Endothelial eNOS Independently Regulate Circulating Nitric Oxide Metabolites and Blood Pressure.
Leo F, Suvorava T, Heuser SK, Li J, LoBue A, Barbarino F, Piragine E, Schneckmann R, Hutzler B, Good ME, Fernandez BO, Vornholz L, Rogers S, Doctor A, Grandoch M, Stegbauer J, Weitzberg E, Feelisch M, Lundberg JO, Isakson BE, Kelm M, Cortese-Krott MM. Leo F, et al. Among authors: li j. Circulation. 2021 Sep 14;144(11):870-889. doi: 10.1161/CIRCULATIONAHA.120.049606. Epub 2021 Jul 7. Circulation. 2021. PMID: 34229449 Free PMC article.
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM. Chen L, et al. Clin Cancer Res. 2022 Jul 1;28(13):2807-2817. doi: 10.1158/1078-0432.CCR-21-4313. Clin Cancer Res. 2022. PMID: 35247906 Free PMC article.
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, Wang H, Yang YS, Huang XY, Cao AY, Li JJ, Di GH, Liu GY, Yang WT, Hu X, Xia Y, Liang QN, Jiang YZ, Shao ZM. Fan L, et al. Lancet Oncol. 2024 Feb;25(2):184-197. doi: 10.1016/S1470-2045(23)00579-X. Epub 2024 Jan 8. Lancet Oncol. 2024. PMID: 38211606 Clinical Trial.
Stealth and pseudo-stealth nanocarriers.
Wen P, Ke W, Dirisala A, Toh K, Tanaka M, Li J. Wen P, et al. Among authors: li j. Adv Drug Deliv Rev. 2023 Jul;198:114895. doi: 10.1016/j.addr.2023.114895. Epub 2023 May 19. Adv Drug Deliv Rev. 2023. PMID: 37211278 Review.
Editorial: Delivery systems in biologics-based therapeutics.
Dirisala A, Li J, Gonzalez-Carter D, Wang Z. Dirisala A, et al. Among authors: li j. Front Bioeng Biotechnol. 2023 Aug 18;11:1274210. doi: 10.3389/fbioe.2023.1274210. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37662436 Free PMC article. No abstract available.
1,015 results